JP Morgan Maintains Overweight on Praxis Precision Medicine, Raises Price Target to $725
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Tessa Romero maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and raises the price target from $700 to $725.
JP Morgan analyst Tessa Romero maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and raises the price target from $700 to $725.
